Earnings summaries and quarterly performance for Athira Pharma.
Executive leadership at Athira Pharma.
Mark Litton
Detailed
President and Chief Executive Officer
CEO
Javier San Martin
Detailed
Chief Medical Officer
Kevin Church
Detailed
Chief Scientific Officer
Mark Worthington
Detailed
General Counsel, Chief Compliance Officer and Corporate Secretary
Robert Renninger
Detailed
Senior Vice President, Finance and Accounting
Board of directors at Athira Pharma.
Research analysts who have asked questions during Athira Pharma earnings calls.
Andrew Tsai
Jefferies
1 question for ATHA
Also covers: ARQT, ATAI, AVDL +13 more
Corinne Jenkins
Goldman Sachs
1 question for ATHA
Also covers: ACRS, ALEC, FULC +5 more
Jason Butler
JMP Citizens
1 question for ATHA
Also covers: ACAD, AQST, CRMD +9 more
Paul Matteis
Stifel
1 question for ATHA
Also covers: ABOS, ACAD, ALKS +11 more
Recent press releases and 8-K filings for ATHA.
Athira Pharma Acquires Rights to Late-Stage Breast Cancer Drug and Secures Funding
ATHA
New Projects/Investments
M&A
- Athira Pharma has acquired rights to lasofoxifene, a Phase III clinical development program for metastatic breast cancer, diversifying its pipeline alongside ATH-1105 for ALS.
- The ELAINE-3 registrational trial for lasofoxifene is more than 50% enrolled, with top-line data expected in mid-2027.
- The company secured $90 million in initial funding, extending its cash runway into 2028, with potential for an additional $146 million from warrants upon completion of ELAINE-3 enrollment, anticipated in mid-2026.
- If approved, lasofoxifene is projected to achieve peak annual U.S. sales approaching $1 billion in a global metastatic ER-positive HER2-negative market expected to grow from $10.9 billion in 2025 to over $15.9 billion by 2029.
20 hours ago
Athira Pharma Acquires Phase III Metastatic Breast Cancer Program
ATHA
M&A
New Projects/Investments
- Athira Pharma announced the acquisition of rights to develop and commercialize lasofoxifene, a Phase III clinical development program for metastatic breast cancer, diversifying its pipeline.
- The company expects top-line data readout in mid-2027 for the ongoing Phase III ELAINE III trial of lasofoxifene, which aims to validate a median Progression-Free Survival (PFS) of approximately 13 months observed in Phase II.
- The target market for ER-positive HER2-negative metastatic breast cancer is projected to grow from $10.9 billion in 2025 to over $15.9 billion by 2029.
- The license agreement for lasofoxifene includes equity, mid- to lower double-digit royalties, and milestones.
21 hours ago
Athira Acquires Rights to Late-Stage Breast Cancer Drug and Secures Funding
ATHA
M&A
New Projects/Investments
- Athira has acquired rights to develop and commercialize lasofoxifene, an innovative Phase III clinical development program for metastatic breast cancer, diversifying its pipeline.
- The company secured $90 million in initial funding, providing a cash runway into 2028, with warrants potentially offering an additional $146 million upon exercise.
- Top-line data from the ELAINE III registrational trial for lasofoxifene is expected in mid-2027, with meaningful data readouts for both lasofoxifene and ATH-1105 (for ALS) anticipated in 2027.
- If approved, lasofoxifene has the potential to achieve peak annual U.S. sales approaching $1 billion in the metastatic ER-positive HER2-negative market, which is projected to grow to over $15.9 billion by 2029.
22 hours ago
Athira Pharma acquires Phase 3 asset and secures up to $236 million in financing
ATHA
M&A
New Projects/Investments
- Athira Pharma, Inc. has acquired exclusive global rights (excluding Asia and certain countries in the Middle East) to lasofoxifene, a Phase 3 clinical asset for metastatic breast cancer, with data from the ELAINE-3 clinical trial expected in mid-2027.
- The company announced an upfront financing of $90 million through a private placement of common stock and warrants, with the warrants providing the potential for an additional $146 million, totaling up to $236 million.
- This financing is anticipated to fund lasofoxifene development through its topline data readout and key regulatory milestones, extending the company's capital runway into 2028.
- As of September 30, 2025, Athira Pharma had $25.2 million in cash, cash equivalents, and investments, and reported a net loss of $22.7 million for the nine months ended September 30, 2025.
1 day ago
Athira Pharma Announces Q3 2025 Results, Continues Strategic Alternatives Exploration
ATHA
Earnings
M&A
- Athira Pharma reported a net loss of $6.6 million, or $1.68 per share, for the quarter ended September 30, 2025, a significant reduction from the $28.7 million net loss, or $7.46 per share, in the same period last year.
- As of September 30, 2025, the company's cash, cash equivalents, and investments totaled $25.2 million, compared to $51.3 million at December 31, 2024.
- The company continues to explore strategic alternatives focused on maximizing stockholder value and has engaged Cantor Fitzgerald & Co. as an advisor in this process.
- Athira presented favorable safety and tolerability results from its Phase 1 clinical trial of ATH-1105 in healthy volunteers, supporting its continued clinical development for amyotrophic lateral sclerosis (ALS).
Nov 6, 2025, 9:09 PM
Athira Pharma Reports Third Quarter 2025 Financial Results and Business Update
ATHA
Earnings
New Projects/Investments
Delisting/Listing Issues
- Athira Pharma reported a net loss of $6.6 million for the quarter ended September 30, 2025, and is exploring strategic alternatives focused on maximizing stockholder value.
- As of September 30, 2025, cash, cash equivalents, and investments totaled $25.2 million, down from $51.3 million as of December 31, 2024.
- The company presented favorable results from the Phase 1 clinical trial of ATH-1105 in healthy volunteers, demonstrating a favorable safety and tolerability profile, dose proportional pharmacokinetics, and CNS penetration, supporting its continued development for ALS.
- A 10-for-1 reverse stock split of Athira’s common stock became effective on September 17, 2025.
Nov 6, 2025, 9:05 PM
Athira Pharma Announces Reverse Stock Split
ATHA
Delisting/Listing Issues
- Athira Pharma, Inc. (NASDAQ: ATHA) announced a 10-for-1 reverse stock split.
- The reverse stock split will become effective on September 17, 2025, with split-adjusted trading expected to begin on September 18, 2025 under the existing ticker symbol "ATHA".
- The primary goal of the split is to increase the price per share to meet the $1.00 minimum bid price requirement for continued listing on Nasdaq.
- This action will combine ten (10) shares of common stock into one, and the total authorized common shares will be reduced from 900,000,000 to 90,000,000.
Sep 11, 2025, 1:03 PM
Athira Pharma Announces Reverse Stock Split
ATHA
Delisting/Listing Issues
Proxy Vote Outcomes
- Athira Pharma, Inc. will effect a 10-for-1 reverse stock split of its common stock.
- The reverse stock split will become effective on September 17, 2025, at 5:00 p.m., Eastern Time, with trading on a split-adjusted basis expected to begin on Nasdaq on September 18, 2025.
- The primary purpose of the split is to increase the price per share to meet the $1.00 minimum bid price requirement for continued Nasdaq listing.
- As a result of the split, the total number of authorized common shares will be reduced from 900,000,000 to 90,000,000, and any fractional shares will be paid out in cash.
Sep 11, 2025, 1:00 PM
Quarterly earnings call transcripts for Athira Pharma.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more